Unbiased AI-powered news
SpaceX shares closed at $131.11 on July 16 after falling more than 3 percent. The close marked the first time the stock traded below its June IPO price of $135.
Los Angeles TimesSpaceX shares closed at $131.11 on July 16 after declining more than 3 percent, the first close below the company's June IPO price of $135. The stock later fell as low as $124 in after-hours trading after the company delayed its planned Starship rocket launch, the first since the firm went public. The company priced its IPO at $135 per share on June 11 and began trading on the Nasdaq on June 12.
Shares rose 19 percent on the first day of trading to as high as $193. The offering raised $75 billion, with underwriters later exercising rights to sell additional shares that brought total proceeds to $86 billion. SpaceX issued $25 billion in additional debt shortly after the IPO.
The stock has fallen every trading day except one since its debut and is now down 41 percent from its post-float peak reached on June 16. Market value has contracted by more than $1.2 trillion from that peak and by nearly $250 billion from the $150 opening price on June 12.
Elon Musk's net worth rose to as much as $1.32 trillion after the IPO before contracting to about $850 billion, according to the Bloomberg Billionaires Index.
Short sellers' positions in the stock have approached $4 billion. SpaceX is scheduled to release its first earnings report as a public company in the coming weeks. That report will trigger the initial expiration of share lockups for longtime investors.
washingtonpost.comFlooding along the Guadalupe River has killed at least one person in central Texas. The same area recorded more than 130 deaths in flash floods last summer. Governor Greg Abbott confirmed the fatality in a Thursday update.
upi.comThe Food and Drug Administration approved enlicitide, sold as Lipfendra, on Thursday. Manufactured by Merck, the pill inhibits PCSK9 and cut LDL levels by up to 60 percent in a 24-week trial of 2,912 participants. It carries a list price of $315 for a 30-day supply and will reach…
flipboard.comEli Lilly will pay $2.8 billion in cash to acquire AtaiBeckley, a developer of psychedelic treatments for mental health conditions. The deal includes up to $1 billion in additional milestone payments. It adds the target’s compounds to Lilly’s neuroscience programs.